Cargando…
Legumain/pH dual-responsive lytic peptide–paclitaxel conjugate for synergistic cancer therapy
After molecule targeted drug, monoclonal antibody and antibody–drug conjugates (ADCs), peptide–drug conjugates (PDCs) have become the next generation targeted anti-tumor drugs due to its properties of low molecule weight, efficient cell penetration, low immunogenicity, good pharmacokinetic and large...
Autores principales: | Zheng, Shanshan, Cai, Yue, Hong, Yulu, Gong, Yubei, Gao, Licheng, Li, Qingyong, Li, Le, Sun, Xuanrong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176665/ https://www.ncbi.nlm.nih.gov/pubmed/35638851 http://dx.doi.org/10.1080/10717544.2022.2081380 |
Ejemplares similares
-
Bioengineered Ferritin Nanocarriers for Cancer Therapy
por: Sun, Xuanrong, et al.
Publicado: (2021) -
Structure and Mechanism of an Aspartimide-Dependent Peptide Ligase in Human Legumain**
por: Dall, Elfriede, et al.
Publicado: (2015) -
Prognostic value of legumain in uveal melanoma
por: WU, TONG, et al.
Publicado: (2016) -
Nuclear Legumain Activity in Colorectal Cancer
por: Haugen, Mads H., et al.
Publicado: (2013) -
Legumain Promotes Atherosclerotic Vascular Remodeling
por: Ozawa, Nana, et al.
Publicado: (2019)